Achillion Pharmaceuticals (ACHN) : The consensus on Achillion Pharmaceuticals (ACHN) based on 6 analyst recommendation on the company stock is 2.33, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 3 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.
Achillion Pharmaceuticals (ACHN) : Average target price received by Achillion Pharmaceuticals (ACHN) is $9.5 with an expected standard deviation of $3.39. The most aggressive target on the stock is $16, whereas the most downbeat target is $7. 6 financial analysts are currently covering the stock.
Achillion Pharmaceuticals (NASDAQ:ACHN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.81 and $7.81 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $8.26. The buying momentum continued till the end and the stock did not give up its gains. It closed at $8.17, notching a gain of 3.81% for the day. The total traded volume was 900,862 . The stock had closed at $7.87 on the previous day.
Also, Equity Analysts at the Brokerage Firm, Leerink Swann, maintains their rating on the shares of Achillion Pharmaceuticals (NASDAQ:ACHN). Leerink Swann has a Market Perform rating on the shares. As per the latest research report, the brokerage house raises the price target to $9 per share from a prior target of $7. The rating by the firm was issued on May 4, 2016. The company shares have dropped -6.64% from its 1 Year high price. On Dec 30, 2015, the shares registered one year high at $10.95 and the one year low was seen on Feb 12, 2016. The 50-Day Moving Average price is $8.76 and the 200 Day Moving Average price is recorded at $8.10.
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.